Features of Internal Audit in Pharmaceutical Industry

Unknown, Preprint OPEN
Tsvetanova, Yulia (2014)
  • Subject: F53 - International Agreements and Observance ; International Organizations | I18 - Government Policy ; Regulation ; Public Health | M42 - Auditing | internal audit, good practices, medicinal products
    • jel: jel:F53 | jel:M42 | jel:I18
    mesheuropmc: education | health care economics and organizations | health services administration | health care facilities, manpower, and services

The review highlights the main features of internal audit by focus on distribution of medicinal products. Recent data suggest internal audit as an antidote to effects of economic recession. The present review reveals internal audit as a tool for competitiveness through implementation of good practices. The purpose of the review is to describe the advantages of internal audit in new institutional frame. The object of analysis is the distribution practice, and more concrete, the wholesale distributors. The analysis was perform by factor analysis and done in response to the tendency for outsource of distribution activities and practical interest in the use of internal audit by implementation of requirements and recommendations for good practices. The results showed that the internal audit in pharmaceutical industry is determinate by two factors: regulatory requirements and complexity of supply chain. The external and the internal environment define five features of internal audit in pharmaceutical industry.
  • References (24)
    24 references, page 1 of 3

    1. I n s t i t u t e o f I n t e r n a l A u d i t o r s. International Professional Practices Framework. 2013.

    2. E u r o p e a n C o m m i s s i o n. Guidelines of 5 November 2013 on Good Distribution Practice of medicinal products for human use. 2013.

    3. M c C o r m i c k, K. Quality and Regulatory Compliance. Butterworth-Heinemann, 2002.

    4. P h a r m a c e u t i c a l Q u a l i t y G r o u p. Pharmaceutical Auditing. Monograph No. 5 (revised). 2001.

    5. W o r l d H e a l t h O r g a n i z a t i o n. WHO Expert Committee on specifications for pharmaceutical preparations. WHO Technical Report Series 957. Geneva, 2009.

    6. I n t e r n a t i o n a l C o n f e r e n c e o n H a r m o n i s a t i o n. Guideline for Good Clinical Practice. 2002.

    7. W o r l d H e a l t h O r g a n i z a t i o n. Good Laboratory Practice (GLP) Handbook. Geneva, 2009.

    8. W o r l d H e a l t h O r g a n i z a t i o n. WHO good manufacturing practices for medicinal products: main principles. Geneva, 2011.

    9. W o r l d H e a l t h O r g a n i z a t i o n. WHO good distribution practices for pharmaceutical products. Geneva, 2010.

    10. E u r o p e a n C o m m i s s i o n. Directive 2011/62/EU of the European Parliament and of the Council of 8 June 2011 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use, as regards the prevention of the entry into the legal supply chain of falsified medicinal products.

  • Metrics
    No metrics available
Share - Bookmark